Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000469133 | SCV000554000 | uncertain significance | Gastrointestinal stromal tumor; Paragangliomas 4; Pheochromocytoma | 2024-01-16 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 147 of the SDHB protein (p.Tyr147Cys). This variant is present in population databases (rs774568101, gnomAD 0.04%). This missense change has been observed in individual(s) with clinical features of SDHB-related conditions (PMID: 28229225, 34309460; Invitae). ClinVar contains an entry for this variant (Variation ID: 412466). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SDHB protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SDHB function (PMID: 28229225). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000492611 | SCV000581187 | likely benign | Hereditary cancer-predisposing syndrome | 2021-09-21 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Mendelics | RCV000708786 | SCV000837735 | uncertain significance | Cowden syndrome | 2018-07-02 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001294088 | SCV001482894 | uncertain significance | Pheochromocytoma | 2019-08-24 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Gene |
RCV001755709 | SCV002005149 | uncertain significance | not provided | 2023-05-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate that this variant may disrupt SDH cellular compartmentalization (Maignan et al., 2017); Observed in individuals with pheochromocytoma or paraganglioma (Maignan et al., 2017; Garrett et al., 2022); This variant is associated with the following publications: (PMID: 28229225, 34426522, 34906457) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002282162 | SCV002570738 | uncertain significance | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | Variant summary: SDHB c.440A>G (p.Tyr147Cys) results in a non-conservative amino acid change located in the Succinate dehydogenase/fumarate reductase N-terminal domain (IPR025192) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 251178 control chromosomes in the gnomAD database, including 1 homozygotes. The observed variant frequency is approximately 473 fold of the estimated maximal expected allele frequency for a pathogenic variant in SDHB causing Hereditary Paraganglioma-Pheochromocytoma Syndrome phenotype (2.2e-07), strongly suggesting that the variant is benign. c.440A>G has been reported in the literature in cohorts of individuals affected with Pheochromocytoma and as a VUS in settings of multigene panel testing among individuals with Pheochromocytomas and paragangliomas (PPGLs) (example, Maignan_2017, Pipitprapat_2021) and one report published a REVEL score of 0.87 for this variant (Garrett_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Paraganglioma-Pheochromocytoma Syndrome. The following publications have been ascertained in the context of this evaluation (PMID: 28229225, 34309460, 34906457). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=4) or likely benign (n=1). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. |